Institutional Investment Pitches
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
HALO licenses a technology, ENHANZE®, that allows large pharmaceutical companies to replace hours on an IV drip for a quick shot under the skin. The technology works...
— John G. Khabbaz
Full equity research memos, financial breakdowns, and hedge fund thesis write-ups are reserved for BSD Research ($50/mo) and Pro subscribers.
Already a Research or Pro subscriber? Sign In
Other investors who've written on Halozyme Therapeutics
No other institutional pitches found for this ticker yet.
More institutional theses from Phoenician Capital
This quarter, we initiated a position in Modern Dental Group, a Hong Kong-listed dental laboratory business producing over two million custom crowns, bridges, veneers and dentures annually for 35,000 dentists across 28 countries. Europe accounts for...
) is a leading provider of subsea equipment rentals. We added to...
A. (WSE: APR) is...